Fig. 1

SF3B2 promotes tumor progression in patients with HNSCC and in mouse xenograft HNSCC models. A Violin plots of correlation between putative copy-number alterations and SF3B2 mRNA expression. HNSCC data from 7 studies were analyzed using cBioPortal [62]. Grey dot: missense mutation with a variant of uncertain significance (VUS); blue dot: not profiled for mutations. Shallow deletion, n = 136; diploid, n = 738; gain, n = 360; amplification, n = 68. P value was calculated using the pairwise Wilcox rank sum test and adjusted with Bonferroni correction. B Kaplan–Meier plot of overall survival in patients with HNSCC. HNSCC data from 7 studies were analyzed using cBioPortal [62]. Patients were stratified into four groups according to SF3B2 expression. C Western blots of SF3B2 and ACTB in wild type and GFP or GFP-SF3B2 stably-expressing FaDu and Detroit562 cells. D Line plots of cell proliferation of GFP or GFP-SF3B2 stably-expressing FaDu and Detroit562 cells. P value was calculated using the Student’s t-test. E Line plots of cell proliferation of siControl or two different siSF3B2-treated FaDu, GFP-FaDu, and GFP-SF3B2-FaDu cells. P value was calculated using the Tukey–Kramer test. F Western blots of SF3B2 and ACTB in siControl or two different siSF3B2-treated wild-type FaDu cells. G Line plots of tumor growth of GFP-FaDu and GFP-SF3B2-FaDu cells or GFP-Detroit562 and GFP-SF3B2-Detroit562 cells in NOD-SCID mice. P value was calculated using Welch’s t-test